

27 Mar 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Novartis builds radioligand therapy franchise; BMS pioneers new checkpoint inhibitors; Russian CRO leader tries to keep Ukraine trials going; Indian pharma and celebrity endorsement; and how R&D spend compares to 10 years ago.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 25 March 2022, including: [Novartis AG](#) builds radioligand therapy franchise; [Bristol Myers Squibb Company](#) pioneers new checkpoint inhibitors; Russian CRO leader tries to keep Ukraine trials going; Indian pharma and celebrity endorsement; and how R&D spend compares to 10 years ago.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Novartis Lays A New Foundation In Prostate Cancer With Second Radioligand Launch](#)" - Scrip, 23 Mar, 2022.)

(Also see "[BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval](#)" - Scrip, 21 Mar, 2022.)

(Also see "[The Russian-Born CRO Leader Trying To Keep Clinical Trials Going In Ukraine](#)" - Scrip, 24 Mar, 2022.)

SCRIP

CITELINE COMMERCIAL

(Also see "[Star Power: How Celebrity Endorsement Is Shaping In India Pharma](#)" - Scrip, 21 Mar, 2022.)

(Also see "[Up, Up And Away: A Comparison Of Industry R&D Spend Now Versus 10 Years Ago](#)" - Scrip, 17 Mar, 2022.)

[Click here to explore this interactive content online](#) ✨